Hong Liu-Seifert
Overview
Explore the profile of Hong Liu-Seifert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2257
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Henley D, Dowsett S, Chen Y, Liu-Seifert H, Grill J, Doody R, et al.
Alzheimers Res Ther
. 2015 Jun;
7(1):43.
PMID: 26120369
Introduction: To facilitate enrollment and meet local registration requirements, sponsors have increasingly implemented multi-national Alzheimer's disease (AD) studies. Geographic regions vary on many dimensions that may affect disease progression or...
12.
Grill J, Raman R, Ernstrom K, Aisen P, Dowsett S, Chen Y, et al.
Alzheimers Res Ther
. 2015 Jun;
7(1):39.
PMID: 26120368
Introduction: Most Alzheimer's disease (AD) clinical trials enroll participants multinationally. Yet, few data exist to guide investigators and sponsors regarding the types of patients enrolled in these studies and whether...
13.
Liu-Seifert H, Andersen S, Lipkovich I, Holdridge K, Siemers E
PLoS One
. 2015 Mar;
10(3):e0119632.
PMID: 25781335
One method for demonstrating disease modification is a delayed-start design, consisting of a placebo-controlled period followed by a delayed-start period wherein all patients receive active treatment. To address methodological issues...
14.
Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, et al.
J Alzheimers Dis
. 2014 Aug;
43(3):949-55.
PMID: 25125457
Background: In patients with Alzheimer's disease (AD), the relationship between cognitive and functional progression is not fully understood; however, functional decline has been postulated to follow cognitive decline. Objective: To...
15.
Doody R, Thomas R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al.
N Engl J Med
. 2014 Jan;
370(4):311-21.
PMID: 24450890
Background: Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted...
16.
Kinon B, Liu-Seifert H, Stauffer V, Jacob J
Clin Schizophr Relat Psychoses
. 2013 Feb;
7(3):115-23.
PMID: 23395836
Background: Elevated prolactin (hyperprolactinemia) has been commonly reported during treatment with some antipsychotic drugs. A decrease in bone mineral density (BMD) may be related to elevated prolactin. The objective of...
17.
Kinon B, Kollack-Walker S, Stauffer V, Liu-Seifert H
J Clin Psychopharmacol
. 2012 May;
32(3):420-2.
PMID: 22561475
No abstract available.
18.
Liu-Seifert H, Ascher-Svanum H, Osuntokun O, Jen K, Gomez J
BMC Psychiatry
. 2011 May;
11:87.
PMID: 21586165
Background: When treating schizophrenia, improving patients' productivity level is a major goal considering schizophrenia is a leading cause of functional disability. Productivity level has been identified as the most preferred...
19.
Liu-Seifert H, Osuntokun O, Feldman P
Compr Psychiatry
. 2011 Feb;
53(1):107-15.
PMID: 21310400
Objectives: Poor treatment response is an important factor contributing to lack of treatment adherence. The goals of this research were to determine whether improvements in Positive and Negative Syndrome Scale...
20.
Liu-Seifert H, Osuntokun O, Godfrey J, Feldman P
Patient Prefer Adherence
. 2010 Nov;
4:369-77.
PMID: 21049089
This analysis examined patient-reported attitudes toward antipsychotic medication and the relationship of these attitudes with clinical outcomes and pharmacotherapy adherence. The analysis included three randomized, double-blind studies in patients with...